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Background: Long-acting β2-adrenergic agonists (LABAs) are recommended in combination with inhaled
corticosteroids (ICSs) for asthma management. Abediterol is a novel, selective, potent, once-daily LABA in development
for treatment of asthma and chronic obstructive pulmonary disease. This study aimed to determine abediterol doses
with similar peak bronchodilatory effect to salbutamol 400 μg, and duration of action compatible with once-daily dosing
in patients with persistent, stable asthma.
Methods: This was a Phase II, randomized, double-blind, double-dummy, crossover, placebo-controlled, dose-ranging
study (ClinicalTrials.gov NCT01425801) in 62 patients with mild-to-moderate asthma who were also receiving an ICS.
Patients received single doses of abediterol 0.313, 0.625, 1.25, or 2.5 μg, salbutamol 400 μg, or placebo in the morning.
Spirometry was performed up to 36 h post-dose; safety and tolerability were assessed throughout the study. The
primary endpoint was change from baseline in peak forced expiratory volume in 1 s (FEV1). Additional endpoints
included trough FEV1, normalized area under the FEV1 curve (FEV1 AUC) up to 24 h post-dose, and peak and trough
forced vital capacity (FVC).
Results: Abediterol produced dose-dependent improvements in peak FEV1 from baseline compared with placebo,
from 0.274 (95% CI 0.221, 0.327) to 0.405 L (95% CI 0.353, 0.458) for abediterol 0.313 to 2.5 μg, respectively (p < 0.0001 all
doses). Abediterol 0.625, 1.25, and 2.5 μg had similar magnitude of peak FEV1 effect to salbutamol. Dose-dependent
changes from baseline in trough FEV1 versus placebo were 0.219 (95% CI 0.136, 0.302) to 0.400 L (95% CI 0.317, 0.483)
for abediterol 0.313 to 2.5 μg, respectively (p < 0.0001). All abediterol doses achieved significant improvements versus
placebo in FEV1 AUC 0–6, 0–12, and 0–24 h, and peak and trough FVC (p < 0.05). Less than 10% of patients experienced
treatment-related adverse events for each dose of abediterol; most were mild to moderate in intensity and the most
common were headache and nasopharyngitis. There were no clinically relevant changes in heart rate.
Conclusions: Abediterol 0.625–2.5 μg provided dose-dependent, clinically and statistically significant bronchodilation
versus placebo in patients with asthma, with a peak effect similar to salbutamol and duration of action compatible with
once-daily dosing. All doses of abediterol were well tolerated.
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The use of β2-adrenergic agonist bronchodilators in
combination with inhaled corticosteroids (ICSs) to manage
the symptoms of asthma is recommended by Global Initia-
tive for Asthma (GINA) guidelines [1]. Currently licensed
bronchodilators include salbutamol, a short-acting β2-
adrenergic agonist (SABA) administered as required [2],
salmeterol and formoterol, two long-acting β2-adrener-
gic agonists (LABAs) administered twice daily in com-
bination with an ICS [3,4], and the recently licensed
vilanterol, a LABA administered once daily in fixed-
dose combination with the ICS fluticasone furoate [5].
There is ongoing interest to develop once-daily medica-
tions to further simplify treatment regimens and im-
prove patient compliance [6].
Abediterol is a novel, once-daily LABA in clinical devel-
opment as a fixed-dose combination with an ICS for the
treatment of asthma and chronic obstructive pulmonary
disease (COPD) [7]. Abediterol displays high affinity for
β2-adrenoceptors, plus a higher functional selectivity for
β2-adrenoceptors over β1-adrenoceptors than formoterol,
indacaterol, vilanterol and olodaterol in cellular models
[7-9]. The potency of abediterol is also higher than salme-
terol and indacaterol in isolated human bronchi and, in
addition to these two LABAs, vilanterol and olodaterol in
animal models [7,10]. Abediterol has a rapid onset and
prolonged duration of action [7,10].
A Phase II clinical trial in patients with asthma pro-
vided results that were consistent with the preclinical
data; abediterol resulted in significant improvements in
lung function at 5 min post-dose that were greater than
improvements seen with salmeterol, and significant
bronchodilation was sustained up to 24 h post-dose
[11]. These characteristics make abediterol an ideal
candidate for once-daily dosing. Moreover, abediterol
has a favorable cardiovascular safety and tolerability
profile: in anesthetized dogs, abediterol had a lesser effect
on heart rate compared with salmeterol, formoterol, and
indacaterol at concentrations that produced comparable
bronchodilation [7,12]. In early phase clinical trials, doses
of abediterol ≤10 μg were safe and well tolerated and did
not demonstrate any clinically relevant effects on heart
rate in healthy subjects [13], patients with asthma [14], or
patients with COPD [15].
Drug regulatory authorities have concerns that exces-
sively high LABA doses may cause unacceptable side ef-
fects [16]. The trough forced expiratory volume in 1 s
(FEV1), measured 24 h after dosing, is an important end-
point to assess once-daily LABA efficacy [16]. The max-
imum effect achieved soon after dosing, otherwise
known as the ‘peak’ effect, is also of interest for efficacy
and safety reasons. A very high peak effect may indicate
high levels of acute drug exposure that could predispose
patients to β-agonist-mediated side effects, such ascardiovascular adverse events, when receiving chronic
treatment [17]. Moreover, the ideal pharmacologic
characteristic of a once-daily LABA is a low ‘peak to
trough ratio’, ensuring relatively stable lung function
throughout the day [18].
The peak effect of salbutamol is well characterized,
and causes acute bronchodilation without safety con-
cerns. The bronchodilator response following single-
dose administration of salbutamol (4 x 100 μg) is com-
monly used as one of the diagnostic tests for asthma, as
recommended by a joint European Respiratory Society
(ERS)/American Thoracic Society (ATS) taskforce [19].
This effect is, therefore, a reasonable benchmark for a
novel LABA to achieve and this degree of acute bron-
chodilation is considered clinically meaningful. A major
regulatory agency recommended that the peak effects of
abediterol should be compared to those of salbutamol to
guide dose selection for further clinical trials in order to
avoid a dose that induces a much greater degree of
bronchodilation than is necessary for clinical effective-
ness, which could increase the potential for safety con-
cerns during chronic treatment.
We report a placebo-controlled, dose-ranging, cross-
over study comparing the acute bronchodilator effects of
abediterol to salbutamol in patients with persistent
stable asthma. The primary aim of the study was to in-
vestigate the peak bronchodilatory effect of abediterol
versus placebo and to confirm it was in the same range
as that of salbutamol. The full profile of lung function
over 24 h, including the trough FEV1, was also mea-
sured. The goal of this study was to enable the selection
of abediterol doses for future long-term clinical trials,
based on a peak effect similar to that of salbutamol
400 μg metered dose inhaler (MDI), coupled with a
trough effect compatible with a 24-h duration of action.




This was a Phase IIa, randomized, double-blind, double-
dummy, 6-way crossover, single-dose, multicenter, dose-
ranging study conducted between August 2011 and
January 2012. The study was conducted in two sites in
the UK and seven in Germany. The study protocol was
approved by an independent ethics committee in each
country (see Additional file 1) and complied with the
Declaration of Helsinki and the International Conference
on Harmonisation and Good Clinical Practice guidelines.
Patients provided written, informed consent.
Following a screening visit and a 12–16 day run-in
period to assess clinical stability, participants were ran-
domized to 1 of 6 treatment sequences according to a bal-
anced Williams design for crossover studies (1:1:1:1:1:1).




Age, mean no. years (SD) 40.9 (11.2)




Cigarette smoking status, n (%)
Former smoker 21 (33.9)
Never smoked 41 (66.1)
Smoking history, mean no. pack-years (SD) 4.6 (3.3)
Asthma duration, mean no. years (SD) 25.5 (13.2)
Asthma severity, n (%)
60%≤ FEV1 < 80% of predicted 46 (74.2)
FEV1 ≥80% of predicted 16 (25.8)
Bronchial reversibilitya, mean % (SD) 21.3 (8.2)
FEV1 absolute reversibility
b, mean L (SD) 0.568 (0.261)
acalculated as 100 x (FEV1 [post-bronchodilator] – FEV1 [pre-bronchodilator]/FEV1
[pre-bronchodilator]); bcalculated as FEV1 (post-bronchodilator) – FEV1
(pre-bronchodilator).
FEV1, forced expiratory volume in 1 s; SD, standard deviation.
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a computer-generated schedule to assign a treatment se-
quence to each patient randomization number. The block
size and randomization schedule were not communicated
to investigators. Patients received abediterol 0.313, 0.625,
1.25, or 2.5 μg, salbutamol 400 μg (administered as four
inhalations with 100 μg per inhalation), or placebo (at
09:00 h ±1 h) at each visit, with a washout period of 7–14
days. A follow-up telephone call to assess safety was made
approximately 2 weeks following the final treatment visit
or premature discontinuation.
Abediterol and placebo to abediterol were admi-
nistered via a multidose dry powder inhaler (Genuair®).
Salbutamol and placebo to salbutamol were adminis-
tered via a pressurized MDI (Ventolin™ Evohaler™). In
order to preserve study blinding, independent, trained
personnel prepared the medication, delivered the device to
patients, and collected the device following inhalation.
Patients
Eligible participants were men or women aged 18–70
years with a clinical diagnosis of persistent asthma (ac-
cording to GINA guidelines) for ≥6 months prior to
screening. Eligible patients had an FEV1 >60% and ≤85%
of the predicted normal value, with an FEV1 reversibility
≥12%, and an absolute increase in FEV1 of ≥200 mL over
their baseline value following inhalation of salbutamol
400 μg at screening. Comparable FEV1 measurements
were required at screening and pre-dose at each visit in
order to ensure there were no carry-over effects from
previous treatment periods (limit of variability ±20%). At
enrollment, all patients were using only an ICS to con-
trol their asthma, and had been on a stable dose and
regimen for at least 4 weeks prior to screening, up to the
equivalent of 1600 μg/day of beclometasone dipropionate,
and had not previously been exposed to abediterol.
Exclusion criteria included: a smoking history within
the past 6 months or >10 pack-years; presence or history
of relevant pulmonary disease or any other clinically
relevant disease or abnormality as judged by the investi-
gator; difficult-to-treat asthma; any respiratory tract in-
fection ≤6 weeks prior to screening; hospitalization or
emergency room treatment for asthma ≤3 months prior
to screening; treatment with β2-antagonists; and positive
laboratory tests for illicit drugs.
The use of anticholinergics, SABAs (other than
salbutamol), LABAs, continuous oral or parenteral
corticosteroids, methyl-xanthines, cromolyn sodium,
nedocromil, leukotriene modifiers, anti-immunoglobulin E,
β1-blocking agents, and other investigational drugs
was prohibited during the study. Patients using prohib-
ited medications underwent up to 6 weeks’ washout be-
fore the screening visit. Salbutamol pressurized MDI
(100 μg/puff) was the only reliever medication permittedand was used on an as-needed basis and avoided 6 h prior
to and during a treatment visit unless absolutely necessary.
Efficacy assessments
Pulmonary function tests were conducted at screening,
pre-dose, and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 14, 23,
24, and 36 h post-dose at each treatment visit using
standardized spirometers at each investigational site
(eResearchTechnology, Philadelphia, PA, USA). Prior
to the first spirometry measure, the technician dem-
onstrated the procedure and allowed the patient two
practice attempts. At each study time point, the ma-
neuvers were repeated until three technically adequate
measurements were made according to ERS/ATS guide-
lines for acceptability and repeatability [20], with a max-
imum of eight attempts allowed.
Safety and tolerability assessments
Treatment-emergent adverse events (TEAEs), including
serious adverse events, were recorded throughout the
study and follow-up period. A physical examination was
performed at screening and at 36 h post-dose following
the last treatment period (Visit 6), and blood pressure
and 12-lead electrocardiogram measures were made at
screening, pre-dose, and at 0.75, 2, 6, 24 h post-dose for
each treatment period, and 36 h post-dose at Visit 6.
Clinical laboratory tests (blood chemistry, hematology,
urinalysis, and a serum pregnancy test) were performed
at screening and at 36 h post-dose at Visit 6. Blood glucose
Figure 1 Diagram of patient flow.
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pre-dose, and at 4, 24 h post-dose for each treatment
period, and 36 h post-dose at Visit 6.
Statistics
The primary efficacy endpoint was change from baseline
in peak FEV1 (defined as the highest FEV1 value ob-
served within 4 h of the administration of the investiga-
tional medicinal product [IMP]) on Day 1. Secondary
endpoints included change from baseline in peak forced
vital capacity (FVC) on Day 1, trough FEV1 (defined as
the highest average of the maneuvers performed at 23–
24 h post IMP administration) and FVC on Day 2,
change from baseline in FEV1 and FVC at each time
point up to 36 h post-dose, and change from baseline in
normalized FEV1 area under the curve (AUC; defined as
the area between baseline FEV1 and the FEV1 curve,
from 0 to × hours divided by × hours) at 0–6, 0–12, and
0–24 h post-dose. In accordance with the GINA guide-
lines, a change in FEV1 of 200 mL was considered clinic-
ally relevant [1].
A population of 48 patients was necessary to achieve
80% power to detect a 150 mL change from baseline in
peak FEV1 for any dose of abediterol compared with pla-
cebo. Assuming a 15% withdrawal rate, the protocol re-
quired at least 54 patients to be randomized.
All reported efficacy assessments were analyzed in the
intention-to-treat population, defined as all randomized
patients who took at least one dose of the IMP (placebo,
abediterol, or salbutamol) and had at least one baseline
and one post-dose FEV1 value for at least one treatment
visit. Safety analyses are reported in the safety popula-
tion, which consisted of all randomized patients who
took at least one dose of the IMP. All statistical analyses
were performed using Statistical Analysis System (SAS
Institute Inc., Cary, NC, USA) version 9.1.3 software.
Efficacy variables were analyzed using an analysis of
covariance model for crossover designs, with fixed-effect
factors of sequence, treatment, and period, patient within
sequence as a random effect, and baseline FEV1 or FVC as
a covariate, as appropriate. Between-treatments com-
parisons were performed by means of contrasts on the
treatment factor. The difference between treatments was
estimated by the difference between the least squares
means. Statistical comparisons between active treatments
and placebo were two-sided hypothesis tests with a signifi-
cance level of 0.05.
Results
Study population
A total of 115 patients were screened, with 62 patients
randomized (40/62 [64.5%] male, mean age 40.9 ± 11.2
years). Patient demographics are presented in Table 1. A
diagram of patient flow is presented in Figure 1. All 62patients were included in the intention-to-treat and
safety populations. One protocol violation occurred
when a patient was inadvertently given the treatment
scheduled for Visit 6 at Visit 5, and vice versa. Data for
this patient were analyzed according to the treatments
received. Four patients withdrew or were discontinued
from the study: two due to inability to comply with the
study schedule, one who did not fulfill stability criteria,
and one for unknown reasons (patient did not return for
the premature discontinuation visit).
Efficacy
Peak FEV1
Mean baseline FEV1 values were similar across all treat-
ment periods, ranging from 2.63 L to 2.69 L. The full
profile of lung function after each treatment is shown in
Figure 2. The onset of action of abediterol was rapid,
with significant bronchodilation compared with placebo
observed at the first study time point (15 min) post-dose
(p < 0.0001 for all doses of abediterol versus placebo,
Figure 2a). All doses of abediterol produced significantly
greater improvements in peak FEV1 from baseline com-
pared with placebo (p < 0.0001 for all doses, Table 2),
and the magnitude of effect of abediterol 0.625, 1.25,
and 2.5 μg was not significantly different from
Figure 2 Change from baseline in FEV1 over time. Data are presented as least squares means with 95% confidence intervals: a) p < 0.0001
versus placebo for salbutamol and all doses of abediterol at all time points; b) p < 0.0001 for all doses of abediterol 0–24 h post-dose and abediterol
1.25 and 2.5 μg 36 h post-dose versus placebo, p = 0.002 and p = 0.01 for abediterol 0.313 and 0.625 μg, respectively, at 36 h post-dose versus placebo.
FEV1, forced expiratory volume in 1 s.
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means differences in change from baseline in peak FEV1
versus placebo were 0.274, 0.322, 0.371, and 0.405 L forabediterol 0.313, 0.625, 1.25, and 2.5 μg, respectively,
and 0.353 L for salbutamol 400 μg (Table 3). Median
time to peak FEV1 was 3 h post-dose for abediterol (all













































































































Data are least squares means (standard error).
atrough values are the mean of the 23 and 24 h post-dose measurements.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus placebo; †p < 0.05, ††p < 0.01, ††††p < 0.0001 versus salbutamol 400 μg (analysis of covariance).
AUC, area under the FEV1 curve; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
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salbutamol 400 μg.
Trough FEV1
Statistically significant increases in FEV1 were sustained
at 24 h post-dose compared with placebo (p < 0.0001 for
all doses of abediterol 0–24 h post-dose, Figure 2b).
Abediterol significantly improved trough FEV1 from
baseline compared with placebo (p < 0.0001 for all doses;
Figure 4). Least squares means differences in change
from baseline in trough FEV1 versus placebo were 0.219 L
(95% CI 0.136, 0.302), 0.259 L (95% CI 0.176, 0.342), 0.332 L
(95% CI 0.249, 0.415), and 0.400 L (95% CI 0.317, 0.483) for
abediterol 0.313, 0.625, 1.25, and 2.5 μg, respectively
(Table 2). The effects of salbutamol on FEV1 were not sus-
tained after 6 h post-dose, as expected for a SABA
(Figure 2b).FEV1 AUC
Change from baseline in normalized FEV1 AUC0–6,
FEV1 AUC0–12, and FEV1 AUC0–24 was significantly
higher for all doses of abediterol versus placebo
(p < 0.0001 for all, Table 2), with dose-related effects ob-
served. The change from baseline in normalized FEV1
AUC0–6 was significantly greater for abediterol 0.625–
2.5 μg versus salbutamol 400 μg (p < 0.05, Table 2).
FVC
Mean baseline FVC values were comparable across treat-
ment periods, ranging from 4.23 L to 4.30 L. Abediterol
produced significantly greater change from baseline inpeak FVC compared with placebo (p < 0.01 for all doses,
Table 2). The change from baseline in peak FVC was
similar to that observed with salbutamol. Additionally,
abediterol significantly improved trough FVC from base-
line compared with placebo (p < 0.05 for all doses,
Table 2). All doses of abediterol significantly (p < 0.05)
increased FVC versus placebo up to 24 h post-dose ex-
cept for the 0.625 μg dose at 12 and 23 h.
Safety and tolerability
The percentage of patients experiencing TEAEs was
similar across all treatment groups (Table 4). Most
TEAEs were mild to moderate in intensity, no patient
discontinued the study due to a TEAE, and there were
no serious adverse events or deaths. The most common
TEAEs were headache and nasopharyngitis, reported by
41.9 and 27.4% of patients, respectively. The percentage
of patients that experienced at least one treatment-
related TEAE was <10% for all doses of abediterol, and
was similar to that of salbutamol and placebo. No clinic-
ally significant changes in serum glucose or potassium
concentrations were observed over time in any of the
treatments groups (Table 5). Minor variations in heart
rate over time were observed for all treatment groups,
including placebo; none were considered to be dose re-
lated or clinically relevant (Table 5). There were no
clinically relevant changes in clinical laboratory tests,
blood pressure, or electrocardiogram parameters.
Discussion
In this study, abediterol 0.313, 0.625, 1.25, and 2.5 μg pro-
vided clinically and statistically significant improvements
Figure 3 Change from baseline in peak FEV1 at Day 1. Data are presented as least squares means ± standard error: p < 0.0001 versus placebo
for all doses of abediterol and salbutamol 400 μg; **p < 0.01, ***p < 0.001, ****p < 0.0001 (analysis of covariance).
FEV1, forced expiratory volume in 1 s.
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persistent, stable asthma. Abediterol doses ≥0.625 μg also
caused bronchodilation compatible with once a day ad-
ministration, as improvements in trough FEV1 >250 mL
compared with placebo were observed. The peak broncho-
dilatory effect of abediterol was similar to that of salbuta-
mol 400 μg for all doses ≥0.625 μg.
A mean increase in peak FEV1 >200 mL is considered
clinically relevant in asthma [1]. This magnitude of
change was exceeded for all doses of abediterol, includ-
ing the lowest dose, 0.313 μg. The primary objective of
this study was to define abediterol doses that caused
peak bronchodilation similar to salbutamol, the most
widely prescribed SABA [21]. High doses of β2-agonistsTable 3 Comparison of peak FEV1 for abediterol versus place
Least–squares me
Abediterol 2.5 μg vs. placebo 0.405 (0.027)
Abediterol 1.25 μg vs. placebo 0.371 (0.027)
Abediterol 0.625 μg vs. placebo 0.322 (0.027)
Abediterol 0.313 μg vs. placebo 0.274 (0.027)
Salbutamol 400 μg vs. placebo 0.353 (0.027)
Abediterol 2.5 μg vs. salbutamol 400 μg 0.0529 (0.0270)
Abediterol 1.25 μg vs. salbutamol 400 μg 0.0181 (0.0269)
Abediterol 0.625 μg vs. salbutamol 400 μg −0.0308 (0.0269)
Abediterol 0.313 μg vs. salbutamol 400 μg −0.0783 (0.0269)
Data included for comparisons of all doses of abediterol with placebo and with salbmay increase the degree of bronchodilation but also can
cause excessive systemic side effects through systemic
absorption [22]. However, the current study demon-
strates that the doses of abediterol from 0.625 to 2.5 μg
induce acute bronchodilation similar to salbutamol, and
therefore treatment with higher doses may not be
warranted.
Significant bronchodilation compared with placebo
was achieved with a range of abediterol doses from
0.313 to 2.5 μg, consistent with the high potency of abe-
diterol demonstrated in preclinical studies that sug-
gested a potential for significant bronchodilation in vivo
[7]. Abediterol has higher potency than formoterol,
salmeterol, indacaterol, olodaterol, and vilanterol inbo and abediterol versus salbutamol











Figure 4 Change from baseline in trough FEV1 at Day 2. Data are presented as least squares means ± standard error: p < 0.0001 versus
placebo for all doses of abediterol; **p < 0.01, ***p < 0.001, ****p < 0.0001 (analysis of covariance).
FEV1, forced expiratory volume in 1 s.
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tency than salmeterol and indacaterol with comparable
potency to formoterol in isolated human bronchi [7].
Based on the results of this preliminary dose-ranging
study and the guidelines published by Chowdhury
et al. [16], the clinically effective dose in asthma is
considered most likely to be in the range of 0.625–
2.5 μg.
Significant bronchodilation compared with placebo
was observed for salbutamol and all doses of abediterol
at the first-assessed time point (15 min) post-dose; this
indicates a rapid onset of action for both salbutamol and
abediterol. Salmeterol and formoterol, both twice-daily
LABAs, are widely used as maintenance therapy in
COPD and asthma due to their longer durations ofTable 4 TEAEs occurring in ≥2% of patients in any treatment









Any TEAE 16 (27.1) 12 (20.7) 18 (30.0)
Headache 7 (11.9) 6 (10.3) 4 (6.7)
Nasopharyngitis 1 (1.7) 0 8 (13.3)
Chest discomfort 2 (3.4) 0 1 (1.7)
Wheezing 1 (1.7) 2 (3.4) 1 (1.7)
Oropharyngeal pain 0 1 (1.7) 0
Cough 2 (3.4) 0 0
TEAE, treatment-emergent adverse event.action compared with salbutamol [6,18]. In clinical
studies in patients with asthma, the onset of action of
formoterol 24 μg is consistently faster than that of
salmeterol 50 μg, with a median onset of action of
3.6 min compared with 31.0 min in one study [23,24].
In vitro experiments in isolated human bronchi suggest
that the onset of action of abediterol is faster than sal-
meterol and is not significantly different from formo-
terol and indacaterol [7].
The prolonged duration of action of abediterol, with
significant improvements in trough FEV1, normalized
FEV1 AUC0–24, and trough FVC relative to placebo, and
significant bronchodilation maintained up to 36 h post-
dose is consistent with the results of previous clinical












16 (26.7) 18 (30.0) 23 (37.7) 51 (82.3)
7 (11.7) 8 (13.3) 7 (11.5) 26 (41.9)
3 (5.0) 4 (6.7) 2 (3.3) 17 (27.4)
0 0 2 (3.3) 5 (8.1)
0 1 (1.7) 0 4 (6.5)
1 (1.7) 0 3 (4.9) 4 (6.5)
1 (1.7) 0 0 3 (4.8)



















4 hours post-dose −0.37 (0.56) −0.24 (0.55) −0.19 (0.71) −0.27 (0.70) −0.16 (0.94) −0.23 (0.74)
24 hours post-dose 0.01 (0.38) 0.00 (0.33) 0.13 (0.51) 0.06 (0.62) 0.11 (0.45) 0.15 (0.59)
Serum potassium (mmol/L)
4 hours post-dose −0.01 (0.36) −0.09 (0.38) −0.01 (0.35) 0.10 (0.37) 0.02 (0.36) −0.04 (0.35)
24 hours post-dose −0.02 (0.37) 0.04 (0.34) 0.05 (0.33) 0.15 (0.32) 0.04 (0.28) 0.05 (0.38)
Heart rate (bpm)
0.75 h post-dose −0.6 (9.1) 2.0 (10.1) −0.7 (6.1) −0.8 (7.5) −1.5 (9.0) −0.8 (6.2)
2 h post-dose −3.4 (8.7) −1.0 (8.0) −2.0 (6.6) −3.4 (8.1) −4.3 (8.4) −3.2 (6.7)
6 h post-dose 5.1 (10.2) 7.2 (7.7) 6.2 (7.1) 6.2 (8.0) 6.4 (9.8) 5.3 (7.2)
24 h post-dose −2.1 (9.8) −1.9 (8.0) −1.6 (6.7) −0.8 (8.4) −0.9 (8.7) −0.6 (7.6)
Data are mean (standard deviation).
bpm, beats per minute.
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study in patients with COPD demonstrated that abedi-
terol 2.5, 5, and 10 μg achieved >200 mL increases in
FEV1 at 24 h, and that this bronchodilatory effect was
greater than that of indacaterol 150 μg, and the duration
of action was similar [25]. Taken together, these results
are compatible with a once-daily dosing regimen in
asthma and COPD.
The convenience of once-daily dosing is likely to im-
prove compliance in patients with asthma, leading to
better patient outcomes [26,27], as shown in various
studies, including that of Wells et al. whereby once-daily
ICS led to improved compliance in patients with asthma
compared with ICS administered multiple times daily
[28]. LABA monotherapy treatment is contra-indicated
in asthma; co-administration with an ICS is mandated,
preferably as a fixed-dose combination to reduce the risk
of monotherapy administration. Development of once-
daily LABAs for use in fixed-dose combinations with
once-daily ICS is important for simplifying treatment
regimens and, therefore, helping improve patient com-
pliance and general asthma management.
The safety and tolerability profile of abediterol in this
study is comparable to that reported in other studies in
the abediterol development program [11-13,25]. Single
doses of abediterol 0.313–2.5 μg were safe and well tol-
erated, and the TEAEs were consistent with the known
safety profile of β2-agonists.Conclusion
Abediterol 0.625–2.5 μg demonstrated a peak broncho-
dilatory response similar to that of a high dose of salbu-
tamol (400 μg) at very low doses, and showed a cleardose–response relationship. Abediterol is a promising
new, highly potent, LABA with a sustained duration of
action and a favorable safety and tolerability profile.
These results suggest that further studies are warranted
to further evaluate the efficacy and safety of abediterol
in combination with ICS in both asthma and COPD.
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